Forum for Science, Industry and Business

Researchers from Dresden discover protein for more mobility

A total of four million children and adults in Germany are affected by one of more than 6,000 rare diseases. Many of these diseases are still rather unexplored, and there is still no effective therapy for the majority of these diseases.

Prof. Martina Rauner und Dr. Ulrike Baschant (v.l.n.r.)

Foto: Medizinische Fakultät Carl Gustav Carus der TU Dresden / Stephan Wiegand

Take Fibrodysplasia Ossificans Progressiva (FOP). For patients, the diagnosis means the progressive ossification of soft tissue and muscles.

Healthy muscles, ligaments and tendons transform into bones - all in the wrong place - resulting in stiffness and permanent immobility as if you were permanently trapped in a cast.

The growth of bone-like structures where usually no bone is (ectopic ossification) may occur without warning or is triggered by a slight bump. The underlying cause is a gene defect that leads to a defective building plan for the ACVR1 receptor.

Scientists of the Bone Lab of the University Hospital at the TU Dresden have now discovered a protein that links two apparently unrelated systems.

Transferrin receptor-2 (Tfr2), responsible for iron metabolism, was discovered as a new component in bone metabolism. Tfr2 binds to so-called bone morphogenetic proteins (BMPs), which are responsible for the mineralization of bone.

Together with an interdisciplinary team of international researchers, the Bone Lab has now discovered that the binding region of Tfr2 can also be used to neutralize BMPs to prevent misplaced bone formation. Professor Martina Rauner and her colleagues were surprised:

"When we saw how potent the binding region of Tfr2 inhibited the undesired soft tissue ossification in the animal model, we realized that this discovery may have the potential for clinical development."

Martina Rauner, biotechnologist and scientific director of the "Bone Lab" has dedicated her career to the study of bone diseases. It took years of intensive collaboration to decipher the therapeutic potential.

So far, there is no suitable therapy for the approximately 700 patients worldwide and the 30 people affected by FOP in Germany. However, now there is new hope, states Dr Ulrike Baschant: "Kymab, a therapeutic anti-body company in Cambridge, will promote the clinical development of Tfr2 based on our discovery in Dresden.”

This landmark discovery is significant not only for patients with FOP, but also for those with more common skeletal disorders, such as heterotopic ossification, a disease that occurs after hip replacement surgery or major trauma.

The two main authors, Martina Rauner and Ulrike Baschant, report about their finding in the journal Nature Metabolism. The discovery of the protein was the result of international cooperation for many years, amongst others with scientists from the University of Torino in Italy.

With the help of a dozen scientists, they worked in the lab to solve another puzzle of science. Martina Rauner is happy that the "newly created knowledge may serve novel therapies that could improve the lives of children and adults with bone diseases". Ulrike Baschant adds, "It is a decisive step towards regaining physical independence and personal freedom!"

Wissenschaftliche Ansprechpartner:

Prof. Dr. Martina Rauner
Scientific Director "Bone Lab"
Medical Clinic III
University Centre for Healthy Ageing
University Hospital and Medical Faculty Carl Gustav Carus of TU Dresden
Phone: +49 351 458 4206
E-Mail: Martina.Rauner@ukdd.de

Originalpublikation:

Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling, in: Nature Metabolismvolume 1, pages111–124 (2019) , doi.org/10.1038/s42255-018-0005-8, https://www.nature.com/articles/s42255-018-0005-8

Weitere Informationen:

https://www.sfb655.de/START/projekte/bereich-b/b13-hofbauer-platzbecker
https://www.kymab.com/
https://www.bone-lab.de/

Stephan Wiegand | idw - Informationsdienst Wissenschaft

Im Focus: The spin state story: Observation of the quantum spin liquid state in novel material

New insight into the spin behavior in an exotic state of matter puts us closer to next-generation spintronic devices

Aside from the deep understanding of the natural world that quantum physics theory offers, scientists worldwide are working tirelessly to bring forth a...

Im Focus: Excitation of robust materials

Kiel physics team observed extremely fast electronic changes in real time in a special material class

In physics, they are currently the subject of intensive research; in electronics, they could enable completely new functions. So-called topological materials...

Im Focus: Electrons in the fast lane

Solar cells based on perovskite compounds could soon make electricity generation from sunlight even more efficient and cheaper. The laboratory efficiency of these perovskite solar cells already exceeds that of the well-known silicon solar cells. An international team led by Stefan Weber from the Max Planck Institute for Polymer Research (MPI-P) in Mainz has found microscopic structures in perovskite crystals that can guide the charge transport in the solar cell. Clever alignment of these "electron highways" could make perovskite solar cells even more powerful.

Solar cells convert sunlight into electricity. During this process, the electrons of the material inside the cell absorb the energy of the light....

Im Focus: The lightest electromagnetic shielding material in the world

Empa researchers have succeeded in applying aerogels to microelectronics: Aerogels based on cellulose nanofibers can effectively shield electromagnetic radiation over a wide frequency range – and they are unrivalled in terms of weight.

Electric motors and electronic devices generate electromagnetic fields that sometimes have to be shielded in order not to affect neighboring electronic...

Im Focus: Gentle wall contact – the right scenario for a fusion power plant

Quasi-continuous power exhaust developed as a wall-friendly method on ASDEX Upgrade

A promising operating mode for the plasma of a future power plant has been developed at the ASDEX Upgrade fusion device at Max Planck Institute for Plasma...